Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Ishares Msci Thailand Etf (THD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Ishares Msci Thailand Etf — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Ishares Msci Thailand Etf trades at $70.3. Which is the better fit depends on your goals.
| ACAD | THD | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $75.05 |
52-Week Low | $20.06 | $51.15 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
THD, the iShares MSCI Thailand ETF, trades at $72.91, up 1.8% on the day, with a bullish technical signal from moving averages and a neutral reading from oscillators. The ETF offers exposure to Thai equities, with a declared dividend of $1.71 for H1-2026. Recent news highlights a significant increase in short interest and ongoing assessments of Thailand's economic policy environment.
The outlook for THD is mixed, with attractive valuations for contrarian investors noted by Seeking Alpha (2026-04-12) but tempered by historical underperformance and political volatility. Key risks include macroeconomic sensitivity to regional central bank policies and geopolitical events, while the primary opportunity lies in a potential rebound if market sentiment on Thailand improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Ishares Msci Thailand Etf
THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →
